XRAY Stock Analysis: Dentsply Sirona | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 2.382m USD | 12M Return: -24.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 53.9M
EPS Trend: -84.6%
Qual. Beats: 0
Rev. Trend: -92.3%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DENTSPLY SIRONA Inc. (XRAY) is a global dental and healthcare products company headquartered in Charlotte, North Carolina, and founded in 1877. It develops, manufactures, and markets dental equipment, cloud-enabled dental solutions, and medical consumables across four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. Its product portfolio spans imaging systems, treatment centers, intraoral scanners, CEREC chairside restoration systems, endodontic and restorative tools, clear aligners (SureSmile), dental implants, regenerative solutions, and catheters and irrigation devices for urology and enterology care. The company was formerly known as DENTSPLY International Inc. before adopting its current name in February 2016.
Listed on NASDAQ as a mid-cap stock in the Health Care Supplies sub-industry, Dentsply Sirona operates a diversified business model that combines capital equipment sales with recurring revenue from consumables, implants, and orthodontic systems. Its integration of digital dentistry tools (such as CEREC, intraoral scanners, and the DS Core platform) positions it within the growing digital dental workflow market, while its Wellspect Healthcare segment extends the franchise into adjacent medical device categories.
- Activist investor demands strategic review and capital allocation changes
- SureSmile clear aligners lose share to Align Technology Invisalign
- Connected Technology Solutions revenue pressured by softer dental equipment orders
| Net Income: -628.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.61 > 1.0 |
| NWC/Revenue: 17.33% < 20% (prev 4.97%; Δ 12.36% < -1%) |
| CFO/TA 0.05 > 3% & CFO 268.0m > Net Income -628.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (199.9m) vs 12m ago 0.05% < -2% |
| Gross Margin: 48.93% > 18% (prev 51.57%; Δ -2.65% > 0.5%) |
| Asset Turnover: 65.27% > 50% (prev 61.47%; Δ 3.80% > 0%) |
| Interest Coverage Ratio: -5.32 > 6 (EBIT TTM -479.0m / Interest Expense TTM 90.0m) |
| A: 0.12 (Total Current Assets 1.84b - Total Current Liabilities 1.21b) / Total Assets 5.23b |
| B: -0.30 (Retained Earnings -1.57b / Total Assets 5.23b) |
| C: -0.08 (EBIT TTM -479.0m / Avg Total Assets 5.64b) |
| D: 0.34 (Book Value of Equity 1.32b / Total Liabilities 3.91b) |
| Altman-Z'' = -0.40 = B |
| DSRI: 1.04 (Receivables 622.0m/604.0m, Revenue 3.68b/3.72b) |
| GMI: 1.05 (GM 51.57% / 48.93%) |
| AQI: 0.88 (AQ_t 0.46 / AQ_t-1 0.52) |
| SGI: 0.99 (Revenue 3.68b / 3.72b) |
| TATA: -0.17 (NI -628.0m - CFO 268.0m) / TA 5.23b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 12.26 with a total of 4,635,490 shares traded. Over the past week, the price has changed by +5.24%, over one month by +22.11%, over three months by +4.70% and over the past year by -24.19%.
Current recommended Stop Loss: 11.50 (which is 6.2% or 1.5 ATR below the current price).
Dentsply Sirona has received a consensus analysts rating of 3.35. Therefore, it is recommended to hold XRAY.
- StrongBuy: 2
- Buy: 2
- Hold: 13
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13.4 | 9.1% |
P/E Forward = 8.3542
P/S = 0.6471
P/B = 1.7897
P/EG = 0.7521
Revenue TTM = 3.68b USD
EBIT TTM = -479.0m USD
EBITDA TTM = -127.0m USD
Long Term Debt = 2.01b USD (from longTermDebt, last quarter)
Short Term Debt = 230.0m USD (from shortTermDebt, last quarter)
Debt = 2.43b USD (from shortLongTermDebtTotal, last quarter) + Leases 95.0m
Net Debt = 2.24b USD (calculated: Debt 2.43b - CCE 190.0m)
Enterprise Value = 4.62b USD (2.38b + Debt 2.43b - CCE 190.0m)
Interest Coverage Ratio = -5.32 (Ebit TTM -479.0m / Interest Expense TTM 90.0m)
EV/FCF = 44.40x (Enterprise Value 4.62b / FCF TTM 104.0m)
FCF Yield = 2.25% (FCF TTM 104.0m / Enterprise Value 4.62b)
FCF Margin = 2.83% (FCF TTM 104.0m / Revenue TTM 3.68b)
Net Margin = -17.06% (Net Income TTM -628.0m / Revenue TTM 3.68b)
Gross Margin = 48.93% ((Revenue TTM 3.68b - Cost of Revenue TTM 1.88b) / Revenue TTM)
Gross Margin QoQ = 48.52% (prev 46.10%)
Tobins Q-Ratio = 0.88 (Enterprise Value 4.62b / Total Assets 5.23b)
Interest Expense / Debt = 3.71% (Interest Expense 90.0m / Debt 2.43b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -378.4m (EBIT -479.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.53 (Total Current Assets 1.84b / Total Current Liabilities 1.21b)
Debt / Equity = 1.84 (Debt 2.43b / totalStockholderEquity, last quarter 1.32b)
Debt / EBITDA = -17.61 (negative EBITDA) (Net Debt 2.24b / EBITDA -127.0m)
Debt / FCF = 21.50 (Net Debt 2.24b / FCF TTM 104.0m)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = -11.14% (Net Income -628.0m / Total Assets 5.23b)
RoE = -41.21% (Net Income TTM -628.0m / Total Stockholder Equity 1.52b)
RoCE = -13.57% (EBIT -479.0m / Capital Employed (Equity 1.52b + L.T.Debt 2.01b))
RoIC = -9.30% (negative operating profit) (NOPAT -378.4m / Invested Capital 4.07b)
WACC = 6.61% (E(2.38b)/V(4.81b) * Re(10.36%) + D(2.43b)/V(4.81b) * Rd(3.71%) * (1-Tc(0.21)))
Discount Rate = 10.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.44 | Cagr: -2.35%
[DCF] Terminal Value 73.10% ; FCFF base≈173.6m ; Y1≈152.2m ; Y5≈123.0m
[DCF] Fair Price = N/A (negative equity: EV 1.97b - Net Debt 2.24b = -261.7m; debt exceeds intrinsic value)
EPS Correlation: -84.57 | EPS CAGR: -7.45% | SUE: 0.0 | # QB: 0
Revenue Correlation: -92.26 | Revenue CAGR: -3.43% | SUE: 2.07 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.35 | Chg30d=-0.06% | Revisions=-56% | Analysts=18
EPS next Quarter (2026-09-30): EPS=0.37 | Chg30d=+0.62% | Revisions=+0% | Analysts=18
EPS current Year (2026-12-31): EPS=1.42 | Chg30d=-0.04% | Revisions=-42% | GrowthEPS=-11.3% | GrowthRev=-2.6%
EPS next Year (2027-12-31): EPS=1.55 | Chg30d=+0.28% | Revisions=-7% | GrowthEPS=+9.2% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: -31% (up=15, down=30)